GLOBAL GENETIC TESTING MARKET 2014-2020 Growth Trends & Forecasts mordorintelligence.com
TABLE OF CONTENTS 1 Introduction 1.1 Report Description 1.2 Research Methodology 2. Genetic Testing Market Overview 2.1 Global Genetic Testing Introduction 2.1.1 Cells and DNA 2.1.2 Gene Families 2.1.3 Gene Mutations 2.1.4 Gene Inheritance 2.1.5 Genetic Consultation 2.2 Genetic Testing Methods 2.2.1 Chromosomal Analysis 2.2.2 Deoxyribonucleic Acid (DNA) Analysis 2.2.3 Metabolites Analysis 2.2.4 Protein Structure Analysis 3 Global Genetic Testing Market Forces 3.1 Market Drivers 3.1.1 Increase of Pipeline Genetic Tests 3.1.2 Aging Population and Prevalence of Cancer 3.1.3 Minimal Procedure Risk 3.1.4 Guide Strategies for Maintaining Health 3.1.5 Guide Treatment Choices for a Variety of Disease Conditions 3.2 Market Restraints 3.2.1 False-Positive and False-Negative Results 3.2.2 Potential Adverse Personal or Societal Consequences Mordor Intelligence 1
3.3 Opportunities 3.2.3 Non-inclusion of Reimbursement Policy 3.3.1 Genetic Counseling 4 Genetic Testing Regulatory Framework 4.1 United States Regulatory Framework 5 Global Genetic Testing Market, By Types 5.1 Overview 5.1.1 Global Genetic Testing Market, By Types, 2014-2020 5.2 Carrier Testing 5.2.1 Global Carrier Testing Market, 2014-2020 5.3 Diagnostic Testing 5.3.1 Global Diagnostic Testing Market, 2014-2020 5.4 Newborn Screening 5.4.1 Global Newborn Screening Market, 2014-2020 5.5 Predictive and Presymptomatic Testing 5.5.1 Global Predictive and Presymptomatic Testing Market, 2014-2020 5.6 Prenatal Testing 5.6.1 Global Prenatal Testing Market, 2014-2020 6 Genetic Testing Market, by Geography 6.1 Overview 6.1.1 Global Genetic Testing Market, by Geography, 2014-2020 6.1.2 Genetic Testing Market Comparative Analysis, by Geography, 2013&2020 6.2 North America 6.2.1 North America Genetic Testing Market, 2014-2020 6.2.1.1 United States 6.2.1.2 Canada 6.2.1.3 Mexico 2
6.3 Europe 6.3.1 Europe Genetic Testing Market, 2014-2020 6.3.1.1 France 6.3.1.2 Germany 6.3.1.3 Italy 6.3.1.4 Spain 6.3.1.5 United Kingdom 6.3.1.6 Rest of Europe 6.4 Asia-Pacific 6.4.1 Asia-Pacific Genetic Testing Market, 2014-2020 6.4.1.1 China 6.4.1.2 India 6.4.1.3 Japan 6.4.1.4 Rest of Asia-Pacific 6.5 Rest of World 6.5.1 Rest of World Genetic Testing Market, by Type, 2014-2020 7 Genetic Testing Market Share Analysis 7.1 Key Players Global Market Share Analysis 7.1.1 Global Genetic Testing Market Share Analysis, by Key Players, 2013 7.1.2 Global Genetic Testing Market, Key Players by Segment 8 Competitive Landscape 8.1 New Product Innovations 8.2 Agreements, Partnerships, Joint Ventures and Collaborations 8.3 Mergers & Acquisitions 9 Company Profiles 9.1 23andMe, Inc. 9.2 Abbott Molecular Mordor Intelligence 3
9.3 Bayer HealthCare AG 9.4 Biocartis SA 9.5 BioHelix Corporation 9.6 BioMerieux S.A. 9.7 Celera Corporation 9.8 Cepheid 9.9 Daan Diagnostics Ltd. 9.10 EKF Diagnostics Holdings plc 9.11 Genentech, Inc. 9.12 GenomicTree, Inc. 9.13 HTG Molecular Diagnostics, Inc. 9.14 IntegraGen S.A 9.15 Laboratory Corporation of America Holdings 9.16 Luminex Corporation 9.17 MolecularMD, Corp. 9.18 Myriad Genetics, Inc. 9.19 Oxford Biodynamics Limited 9.20 Pacific Biosciences of California, Inc. 9.21 Qiagen N.V. 9.22 Roche Diagnostics Limited 9.23 Seegene, Inc. 9.24 Sequenom, Inc. 9.25 Siemens Healthcare 9.26 Transgenomic, Inc. 10 Appendix 10.1 Secondary Sources 10.2 Disclaimer
LIST OF TABLES Table 1: Global Genetic Testing Market for 2010-2020 by Region (In US$ Million) Table 2: Global Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 3: Global Carrier Testing Market for 2010-2020 by Region (In US$ Million) Table 4: Global Diagnostic Testing Market for 2010-2020 by Region (In US$ Million) Table 5: Global Newborn Screening Market for 2010-2020 by Region (In US$ Million) Table 6: Global Predictive & Presymptomatic Testing Market for 2010-2020 by Region (In US$ Million) Table 7: Global Prenatal Testing Market for 2010-2020 by Region (In US$ Million) Table 8: North American Genetic Testing Market for 2010-2020 by Region (In US$ Million) Table 9: North American Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 10: United States Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 11: Canadian Genetic Testing Market for 2010-2020 (In US$ Million) Table 12: Mexican Genetic Testing Market for 2010-2020 (In US$ Million) Table 13: European Genetic Testing Market for 2010-2020 by Region (In US$ Million) Table 14: European Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 15: French Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 16: German Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 17: Italian Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 18: Spanish Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 19: United Kingdom Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 20: Rest of Europe Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 21: Asia-Pacific Genetic Testing Market for 2010-2020 by Region (In US$ Million) Table 22: Asia-Pacific Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 23: Chinese Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 24: Indian Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 25: Japanese Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 26: Rest of Asia-Pacific Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Table 27: Rest of World Genetic Testing Market for 2010-2020 by Segment (In US$ Million) Mordor Intelligence 5
SAMPLE EXCERPTS FROM THE REPORT 2.1 Global Genetic Testing Market Introduction Genetic testing examines a DNA sample for gene changes, or it may analyze the number, arrangement and characteristics of the chromosomes. The genetic testing may be performed on samples of blood, semen, urine, saliva, stool, body tissues, bone or hair. It looks for specific inherited changes (mutations) in a person s chromosomes, genes or proteins. Genetic mutations can have several effects on health ranging from harmful, beneficial, neutral (no effect), or uncertain. Overall, inherited mutations are thought to play a role in about 5 to 10 percent of all cancers. 3.1.2 Aging Population and Prevalence of Cancer The United States cancer testing market alone is estimated to be roughly $10-12 billion. The prevalence of cancer is expected to increase as the US population ages. Approximately 75-80% of all cancers diagnosed in people aged 55 or older and is expected to increase by 2020. According to the United Nations Department of Economic and Social Affairs, the number of senior citizens (aged 60 years or over) is 841 million in 2013 and is expected to be more than 2 billion by 2050. The global share of senior citizens (aged 60 years or over), which is 11.7 percent in 2013, will continue to grow as a proportion of the world population, reaching 21.1 percent by 2050. This clearly projects cancer as the fastest growing segment of genetic testing across the globe. 3.2.2 Potential Adverse Personal or Societal Consequences Personal Genome Testing is susceptible to misunderstanding and misinterpretation due to the complexity of genetic information coupled with the limited predictive ability of the tests themselves. Psychological risks, health risks and societal risks are some of the ramifications expected from personal genome testing as a result of its limited clinical validity.
Adverse psychological risks are well-known from clinical genetic testing such as emotional distress, depression or survivor guilt as a result of test outcomes. These are not to be expected from genetic profiling, at least to the same extent. As test outcomes for multifactorial diseases lack clinical validity, they are much more likely to lead to epistemic uncertainty than to the major psychological impact known from clinical genetics. Health risks are frequently argued for multifactorial diseases. Because of false reassurance on the basis of testing of limited clinical validity, lead patients or consumers adopt unhealthier lifestyles, neglect standard preventive measures and neglect regular screening - thereby harming their health. Indirect economic risks and loss of public confidence are two perceived societal risks involved with the low clinical validity of personal genome testing. On the basis of personal genome test results, consumers may turn to their physicians for advice and follow-up research or medication. Due to uncertain results, from the view of clinical validity, most of the follow-up will be unnecessary and will only drive up the costs of public health care. 5.3 Diagnostic Testing Diagnostic testing represents the slowest growing segment within the global market for genetic testing. This category of testing has been employed for eliminating the possibility of a specific genetic or chromosomal condition. Several instances of diagnostic genetic testing have been utilized for confirming a diagnosis in cases where a specific condition was suspected to exist. These tests have relied on physical mutations and symptoms. While diagnostic testing can be availed at any time in an individual s lifetime, it is not available for all genes or all genetic disorders. Diagnostic test results can play a role in determining an individual s preferences as to healthcare and disease management. Mordor Intelligence 7
SAMPLE TABLES Global Diagnostic Testing Market for 2010-2020 by Region (In US$ Million) Region 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 % CAGR (2014-2020) North America xx xx xx 497.36 xx xx xx xx xx xx xx xx Europe 318.29 xx xx xx xx xx xx xx xx xx xx 13.55 Asia-Pacific xx xx xx xx xx xx xx xx xx 220.16 xx xx Rest of World xx xx xx xx xx xx xx xx xx xx xx xx Total xx xx xx 1,139.72 xx xx xx xx xx xx xx 13.96 Global Predictive & Presymptomatic Testing Market for 2010-2020 by Region (In US$ Million) Region 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 % CAGR (2014-2020) North America 701.59 xx xx xx xx xx xx xx xx xx xx xx Europe xx xx xx 799.94 xx xx xx xx xx xx xx xx Asia-Pacific xx xx xx xx xx xx 233.74 xx xx xx xx xx Rest of World xx xx xx xx xx xx xx xx xx xx xx 14.93 Total xx xx 1,914.32 xx xx xx xx xx xx 4,772.27 xx 16.01
European Genetic Testing Market for 2010-2020 by Region (In US$ Million) Region 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 % CAGR (2014-2020) France xx 1,104.60 xx xx xx xx xx xx xx xx xx 15.34 Germany xx xx xx xx xx xx xx 2,698.03 xx xx xx xx Italy xx xx xx xx 879.60 xx xx xx xx xx xx xx Spain xx xx xx xx xx xx xx xx xx xx xx xx United Kingdom xx xx 1,078.08 xx xx xx xx xx xx xx xx 16.59 Rest of Europe xx xx xx xx xx xx xx xx xx xx xx xx Total xx xx xx xx xx xx xx xx 11,669.55 xx xx 15.85 Mordor Intelligence 9
ABOUT US Mordor Intelligence is a global market research and consulting firm. Our singular focus is to provide research insights for business success. Our research team has expertise in diverse fields like Agriculture, Healthcare, ICT, Chemicals, Manufacturing, Logistics, Electronics and Automotive. However diverse the expertise maybe, everyone in our team shares one common trait - we love data and we love providing solutions to clients using that data even more. Seeing your business flourish based on our solutions and strategy is what we love the most. Disclaimer Mordor Intelligence Reports and their contents, including all the analysis and research containing valuable market information, are provided to a select group of customers in response to orders. Our customers acknowledge when ordering that Mordor Intelligence strategic analysis services are for our customers internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Mordor Intelligence takes no responsibility for any incorrect information supplied to us by manufacturers or users. No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited. For information regarding permissions and sales, please contact: info@mordorintelligence.com
! Mordor Intelligence LLP No. 30, Padma Nilaya, Chola Nagar Bangalore, Karnataka, India 560032 +1 781 881 1110 info@mordorintelligence.com Copyright 2014 Mordor Intelligence LLP All Rights Reserved. This document contains highly confidential information and is the sole property of Mordor Intelligence LLP. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Mordor Intelligence LLP. 7 Mordor Intelligence!